Ahler, D. J., and G. Sood. 2018. The parties in our heads: Misperceptions about party composition and their consequences. Journal of Politics 80(3):964–981. https://doi.org/10.1086/697253 Article Google Scholar Auter, Z. J., and J. A. Fine. 2016. Negative campaigning in the social media age: Attack advertising on Facebook. Political Behavior 38:999–1020. https://doi.org/10.1007/s11109-016-9346-8 Article Google Scholar Bettarelli, L., and E. Van Haute. 2022.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by van Erkel
Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases - CardioVascular and Interventional Radiology
Abstract Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver.
The Role of Consent Form Design Under GDPR: A Survey Experiment
The 2018 implementation of the General Data Protection Regulation (GDPR) in the European Union has triggered widespread concern in the scientific community that GDPR requirements for the processing of personal data may introduce severe limitations for research (EPSR, 2019). The GDPR framework establishes a series of legal rules that researchers must follow to obtain informed consent from individuals whose personal data will be processed as part of the research.
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial | CardioVascular and Interventional Radiology
Abstract To define a safe treatment dose of ipilimumab (IPI) and nivolumab (NIVO) when applied in combination with percutaneous hepatic perfusion with melphalan (M-PHP) in metastatic uveal melanoma (mUM) patients (NCT04283890), primary objective was defining a safe treatment dose of IPI/NIVO plus M-PHP. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAEv4.03). Secondary objective was response rate, PFS and OS.
Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial) | CardioVascular and Interventional Radiology
Abstract To investigate the biodistribution of holmium-166 microspheres (166Ho-MS) when administered after radiofrequency ablation (RFA) of early-stage hepatocellular carcinoma (HCC). The aim is to establish a perfused liver administration dose that results in a tumoricidal dose of holmium-166 on the hyperaemic zone around the ablation necrosis (i.e. target volume).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with van
Contact van, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack